UO Immunoterapia e Laboratorio TCS, IRCCS IRST
Welcome,         Profile    Billing    Logout  
 24 Trials 
41 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Rosa, Francesco G De
XRAY VISION, NCT05386550 / 2022-001144-18: Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants

Terminated
3
166
Europe, Canada, Japan, US, RoW
Xevinapant (Debio 1143), IMRT, Placebo
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Head and Neck Cancer
08/24
08/24
COREVAX-1, NCT02919644 / 2015-000894-11: Vaccination with Autologous Dendritic Cells Loaded with Autologous Tumour Homogenate After Curative Resection for Stage IV Colorectal Cancer.

Recruiting
2
19
Europe
autologous dendritic cells loaded with autologous tumour homogenate, IL2
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
Stage IV Colorectal Cancer, Curative Resection
12/26
12/31
FORTRESS, NCT02979951: Fosfomycin I.v. for Treatment of Severely Infected Patients

Recruiting
N/A
1000
Europe
Infectopharm Arzneimittel GmbH, INPADS GmbH, Dr. Oestreich + Partner GmbH
Bacterial Infections, Bone Diseases, Infectious, Osteomyelitis, Central Nervous System Bacterial Infections, Meningitis, Bacterial, Encephalitis, Brain Abscess, Urinary Tract Infections, Respiratory Tract Infections, Pneumonia, Bacterial, Skin Diseases, Bacterial, Soft Tissue Infections, Intraabdominal Infections, Sepsis, Bacteremia, Endocarditis, Bacterial
12/30
12/30
Guidoboni, Massimo
KEYNOTE-D18, NCT05155254 / 2021-004594-32: IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)

Active, not recruiting
3
407
Europe, US, RoW
IO102-IO103, Pembrolizumab
IO Biotech, Syneos Health, Merck Sharp & Dohme LLC
Metastatic Melanoma, Unresectable Melanoma
07/25
09/27
ABSIDE, NCT01973322 / 2012-001410-41: Vaccination With Autologous Dendritic Cells Loaded With Autologous Tumor Lysate or Homogenate Combined With Immunomodulating Radiotherapy and/or Preleukapheresis IFN-alfa in Patients With Metastatic Melanoma: a Randomized "Proof-of-principle" Phase II Study

Completed
2
34
Europe
arm 1: DC Vaccine + RT, vaccine + radiotherapy, arm 2: DC Vaccine + IFN-alfa, vaccine + drug, arm 3: both arm 1 and 2 + RT, vaccine + radiotherapy + drug, arm 4: DC Vaccine, vaccine
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
Malignant Melanoma of Skin Stage III, Malignant Melanoma of Skin Stage IV
09/23
06/24
NCT05299580 / 2019-004760-21: "Dabrafenib and Trametinib in Circulating Free DNA BRAFV600 Mutated Metastatic Melanoma Patients: a Prospective Phase II, Open Label, Multicentre Study - (Bioliquid TAILOR Study - BIOTAILOR)"

Withdrawn
2
35
Europe
dabrafenib, Trametinib
Fondazione Melanoma Onlus, Novartis Farma S.p.A.
Melanoma
03/23
03/23
NCT05529316: A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma

Active, not recruiting
2
174
Europe, US, RoW
Botensilimab, AGEN1181, Balstilimab, AGEN2034
Agenus Inc.
Advanced Melanoma
02/28
02/28
NEO-TIM, NCT04722575 / 2018-004841-17: Combination or Sequence of Vemurafenib, Cobimetinib, and Atezolizumab in High-risk, Resectable Melanoma

Active, not recruiting
2
95
Europe
Cobimetinib 20 MG Oral Tablet, Cotellic, Vemurafenib 240 Mg Oral Capsule, Zelboraf, Atezolizumab 1200 MG in 20 ML Injection, Tecentriq
Fondazione Melanoma Onlus, Clinical Research Technology S.r.l.
Melanoma
12/23
06/27
MESOVAX, NCT03546426: Pembrolizumab Plus Autologous Dendritic Cell Vaccine in Patients with PD-L1 Negative Advanced Mesothelioma Who Have Failed Prior Therapies

Active, not recruiting
1
18
Europe
Pembrolizumab, Autologous dendritic cells, Interleukin-2
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
Mesothelioma, Malignant, PD-L1 Negative, Advanced Cancer, Progressive Disease
01/27
09/28
NCT04759846: Hepatic Impairment Study of Encorafenib in Combination With Binimetinib in BRAF Melanoma

Withdrawn
1
12
Europe, RoW
Encorafenib + Binimetinib, Braftovi + Mektovi
Pierre Fabre Medicament
BRAF V600 Mutation, Unresectable Melanoma, Metastatic Melanoma, Hepatic Impairment
05/23
05/23
Giorgi, Ugo De
NCT04460807 / 2018-000693-30: Exemestane in Hormone Receptor Positive High Grade Ovarian Cancer

Terminated
3
23
Europe
Exemestane, Mestane, Placebo oral tablet
Ente Ospedaliero Ospedali Galliera, Istituto Di Ricerche Farmacologiche Mario Negri, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Federation of Italian Cooperative Oncology Groups
Ovarian Cancer
04/23
04/23
innovaTV 301, NCT04697628 / 2019-001655-39: Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer

Active, not recruiting
3
502
Europe, Canada, Japan, US, RoW
tisotumab vedotin, TIVDAK, PF-08046057, topotecan, vinorelbine, gemcitabine, irinotecan, pemetrexed
Seagen, a wholly owned subsidiary of Pfizer, Genmab
Cervical Cancer
07/23
05/26
postMONARCH, NCT05169567 / 2021-002301-10: Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer

Active, not recruiting
3
368
Europe, US, RoW
Abemaciclib, Fulvestrant, Placebo
Eli Lilly and Company, Eli Lilly and Company
Breast Neoplasm, Neoplasm Metastasis
02/24
02/26
PEACE III, NCT02194842 / 2014-001787-36: Phase III Radium 223 mCRPC-

Active, not recruiting
3
446
Europe, Canada, RoW
Ra223, Enzalutamide
European Organisation for Research and Treatment of Cancer - EORTC, Bayer, Astellas Pharma Europe Ltd., UNICANCER, Canadian Urologic Oncology Group, Latin American Cooperative Oncology Group, Cancer Trials Ireland
Prostate Cancer
02/24
12/28
PEGASUS, NCT02799706: Trial Comparing Irradiation Plus Long Term Adjuvant Androgen Deprivation With GnRH Antagonist Versus GnRH Agonist Plus Flare Protection in Patients With Very High Risk Localized or Locally Advanced Prostate Cancer

Active, not recruiting
3
885
Europe
Degarelix, approved GnRH agonist, Radiotherapy
European Organisation for Research and Treatment of Cancer - EORTC
Prostate Cancer
08/23
06/26
NCT02584478 / 2021-003871-32: Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002)

Active, not recruiting
3
294
Europe, US, RoW
AL3818, Anlotinib Hydrochloride, Anlotinib, Catequentinib, Paclitaxel, Pegylated Liposomal Doxorubicin (PLD), Topotecan, Daily Topotecan, Weekly Topotecan, Carboplatin, Paraplatin, Taxol
Advenchen Laboratories, LLC, Advenchen Laboratories, LLC
Endometrial Carcinoma, Ovarian Carcinoma, Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma, Cervical Carcinoma
10/24
12/24
ZEST, NCT04915755 / 2020-003973-23: Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease

Calendar Jan 2025 - Dec 2025: Pivotal data from ZEST trial for HER2-negative BRCA-mutated or triple-negative breast cancer
Active, not recruiting
3
43
Europe, Canada, Japan, US, RoW
Niraparib, Placebo
GlaxoSmithKline
Neoplasms, Breast
06/24
12/25
ELAINE 3, NCT05696626: Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

Recruiting
3
500
Europe, Canada, US, RoW
Lasofoxifene in combination with abemaciclib, Fulvestrant in combination with abemaciclib
Sermonix Pharmaceuticals Inc.
Metastatic Breast Cancer
04/27
04/28
CYCLONE 3, NCT05288166: A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)

Active, not recruiting
3
900
Europe, Canada, Japan, US, RoW
Abemaciclib, LY2835219, Abiraterone, Prednisone or Prednisolone, Placebo for Abemaciclib
Eli Lilly and Company
Prostatic Neoplasms, Neoplasm Metastasis, Urogenital Neoplasms, Physiological Effects of Drugs, Antineoplastic Agents, Antineoplastic Agents, Hormonal, Androgens, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Abiraterone Acetate, Steroid Synthesis Inhibitors, Cytochrome P-450, Enzyme Inhibitors, Prednisone, Prednisolone, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6
02/24
10/27
PEACE6-Unfit, NCT04916613 / 2020-003663-26: ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable)

Recruiting
3
300
Europe
Darolutamide 300 mg, Nubeqa®, Placebo, Androgen deprivation therapy, ADT
UNICANCER, Bayer
Prostate Cancer Metastatic
03/28
09/37
TREAT ctDNA, NCT05512364: Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse

Recruiting
3
220
Europe
Elacestrant, Tamoxifen, Letrozole 2.5mg, Anastrozole 1mg, Exemestane 25 MG
European Organisation for Research and Treatment of Cancer - EORTC, Breast International Group, Menarini Group
ER-positive Breast Cancer, HER2-negative Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer
07/28
05/30
LEPRE, NCT05601700 / 2020-003066-39: Letrozole for Estrogen/Progesterone Receptor Positive Low-grade Serous Epithelial Ovarian Cancer ( Trial)

Recruiting
3
132
Europe
Letrozole tablets, carboplatin AUC 5 and paclitaxel 175 mg/m2
Ente Ospedaliero Ospedali Galliera, Istituto Di Ricerche Farmacologiche Mario Negri, Humanitas Hospital, Italy
Carcinoma, Ovarian Epithelial, Low Grade Serous Adenocarcinoma of Ovary
09/29
09/29
ENGOT en-21, NCT05797831: Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer

Recruiting
2/3
268
Europe, Canada, US, RoW
Navtemadlin, KRT-232, Navtemadlin Placebo
Kartos Therapeutics, Inc., European Network of Gynaecological Oncological Trial Groups (ENGOT), GOG Foundation
Endometrial Cancer
08/25
07/27
NCT02533765 / 2014-005095-28: Olaparib as Salvage Treatment for Cisplatin-resistant Germ Cell Tumor

Completed
2
18
Europe
Olaparib, AZD2281
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
Neoplasms, Germ Cell and Embryonal
09/18
02/23
LU-PSMA, NCT03454750 / 2016-002732-32: Radiometabolic Therapy (RMT) With 177Lu PSMA 617 in Advanced Castration Resistant Prostate Cancer (CRPC)

Completed
2
143
Europe
177Lu-PSMA
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
Metastatic Castration Resistant Prostate Cancer, 68Ga-PSMA PET/CT Positive
05/24
05/24
HERMIONE-7, NCT04227327: Study Evaluating Abemaciclib + Aromatase Inhibitors in HR+, HER2- Advanced Breast Cancer Patients

Active, not recruiting
2
31
Europe
Abemaciclib, Aromatase Inhibitors
University of Milano Bicocca
Advanced Breast Cancer
12/23
12/23
NCT05085002 / 2021-005238-40: A Study of Lerociclib in Participants With Advanced Breast Cancer

Terminated
2
100
Europe, US, RoW
Lerociclib + Letrozole or Fulvestrant
EQRx, Inc.
Advanced Breast Cancer
11/23
11/23
SGNLVA-005, NCT04032704 / 2019-001946-17: A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors

Terminated
2
205
Europe, US, RoW
ladiratuzumab vedotin, SGN-LIV1A, pembrolizumab, Keytruda
Seagen Inc., Merck Sharp & Dohme LLC
Small Cell Lung Cancer, Non-small Cell Lung Cancer, Squamous, Non-small Cell Lung Cancer, Non-squamous, Head and Neck Squamous Cell Carcinoma, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Prostate Cancer, Melanoma
11/23
11/23
ROME, NCT04591431 / 2018-002190-21: The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy

Active, not recruiting
2
400
Europe
Erlotinib, Trastuzumab, Trastuzumab emtansine, Pertuzumab, Lapatinib, Everolimus, Vemurafenib, Cobimetinib, Alectinib, Brigatinib, Palbociclib, Ponatinib, Vismogedib, Itacitinib, Ipatasertib, Entrectinib, Atezolizumab, Nivolumab, Ipilimumab, Pemigatinib, Oncology Drugs, Pralsetinib, Selpercatinib, Talazoparib, Tepotinib, Alpelisib
Fondazione per la Medicina Personalizzata
Breast Cancer, Gastrointestinal Cancer, Non Small Cell Lung Cancer, Other Cancer
12/24
06/25
JAVELIN Bladder Medley, NCT05327530: A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma

Active, not recruiting
2
256
Europe, Canada, US, RoW
Avelumab, MSB0010718C, Sacituzumab Govitecan, IMMU-132, Trodelvy™, GS-0132, M6223, NKTR-255
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany; Gilead Sciences; Nektar Therapeutics
Locally Advanced or Metastatic Urothelial Carcinoma
01/25
01/25
RAPSON, NCT03230734 / 2016-004452-29: Sequencing of Radium-223 and Docetaxel in Symptomatic Bone-only Metastatic Castration-resistant Prostate Cancer

Active, not recruiting
2
70
Europe
Radium-223, Docetaxel
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori, Bayer
Metastatic Castration-resistant Prostate Cancer
07/25
07/25
PREcoopERA, NCT05896566: A Window-of-Opportunity Trial of Giredestrant +/- Triptorelin vs. Anastrozole + Triptorelin in Premenopausal Patients With ER-positive/HER2-negative Early Breast Cancer

Recruiting
2
220
Europe
Giredestrant, Triptorelin, Anastrozole
ETOP IBCSG Partners Foundation, Hoffmann-La Roche
Breast Cancer
06/26
06/26
BIO-META, NCT02284581: Evaluation of Medical Treatments in MBC Patients According Biological Subtype and Line of Treatments

Recruiting
N/A
10000
Europe
Consorzio Oncotech
Metastatic Breast Cancer
06/23
12/25
IRSTB030, NCT03381326: CTC, Free DNA, Stem Cells and EMT-related Antigens as Biomarkers of Activity of Cabazitaxel in CRPC.

Active, not recruiting
N/A
104
Europe
blood and FFPE sample collection
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
Prostate Cancer, Metastatic Cancer, Castration-resistant Prostate Cancer, Circulating Tumor Cells
10/19
12/23
HERMIONE-13, NCT05173103: Retrospective Study of 2nd-line Therapies After CDK4/6i + Hormonal Therapy in HR+/HER2- Advanced Breast Cancer

Recruiting
N/A
150
Europe
University of Milano Bicocca
Advanced Breast Cancer, Hormone Receptor Positive Breast Carcinoma, HER2-negative Breast Cancer
01/24
01/24
NCT06235268: Prospective and Multicenter Italian Registry of Locally Advanced-Metastatic Urothelial Carcinoma

Recruiting
N/A
1000
Europe
Active systemic or non-systemic treatment (palliative or observation procedure)
Federation of Italian Cooperative Oncology Groups
Carcinoma, Urothelial
11/25
11/25
NCT04416672: Validation of the Italian Version of the PRO-CTCAE

Recruiting
N/A
3675
Europe
PRO-CTCAE items
National Cancer Institute, Naples
Malignant Neoplasms
07/24
07/24
Ridolfi, Laura
NCT01884961 / 2012-001786-32: Radiotherapy As an Immunological Booster in Patients with Metastatic Melanoma or Renal Cell Carcinoma Treated with High-dose Interleukin-2

Completed
2
46
Europe
Boost of radiotherapy + high dose IL-2 treatment
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
Metastatic Renal Cell Cancer, Malignant Melanoma, Metastatic
06/21
01/25
RaC-Ad, NCT04166006 / 2019-000793-27: A Phase II Study on Adjuvant Vaccination with Dendritic Cells Loaded with Autologous Tumor Homogenate in Resected Stage IV Rare Cancers.

Recruiting
2
51
Europe
Autologous DC vaccine, Interleukin-2
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori, IRST IRCCS
Head Neck Tumors, Neuroendocrine Tumors, Soft Tissue Sarcoma, Rare Cancer, Vaccination
04/27
12/31
Combi G-Vax, NCT04523688 / 2020-003755-15: Vaccination with Autologous Dendritic Cells Loaded with Autologous Tumour Homogenate in Glioblastoma

Recruiting
2
28
Europe
Autologous Dendritic Cells (DC) vaccine, Temozolomide
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori, IRST IRCCS
Glioblastoma, Vaccination
07/25
12/25
OMNIA-1, NCT05578872 / 2021-006711-29: A Study of ANV419 Alone or in Combination with Approved Treatment in Patients with Cutaneous Melanoma ().

Completed
1/2
29
Europe, US
ANV419, Pembrolizumab, Ipilimumab
Anaveon AG, Anaveon AG
Melanoma (Skin), Cutaneous Melanoma, Adult Disease, Advanced Solid Tumor, Metastatic Melanoma
08/24
08/24
Lolli, Cristian
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Rosa, Francesco G De
XRAY VISION, NCT05386550 / 2022-001144-18: Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants

Terminated
3
166
Europe, Canada, Japan, US, RoW
Xevinapant (Debio 1143), IMRT, Placebo
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Head and Neck Cancer
08/24
08/24
COREVAX-1, NCT02919644 / 2015-000894-11: Vaccination with Autologous Dendritic Cells Loaded with Autologous Tumour Homogenate After Curative Resection for Stage IV Colorectal Cancer.

Recruiting
2
19
Europe
autologous dendritic cells loaded with autologous tumour homogenate, IL2
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
Stage IV Colorectal Cancer, Curative Resection
12/26
12/31
FORTRESS, NCT02979951: Fosfomycin I.v. for Treatment of Severely Infected Patients

Recruiting
N/A
1000
Europe
Infectopharm Arzneimittel GmbH, INPADS GmbH, Dr. Oestreich + Partner GmbH
Bacterial Infections, Bone Diseases, Infectious, Osteomyelitis, Central Nervous System Bacterial Infections, Meningitis, Bacterial, Encephalitis, Brain Abscess, Urinary Tract Infections, Respiratory Tract Infections, Pneumonia, Bacterial, Skin Diseases, Bacterial, Soft Tissue Infections, Intraabdominal Infections, Sepsis, Bacteremia, Endocarditis, Bacterial
12/30
12/30
Guidoboni, Massimo
KEYNOTE-D18, NCT05155254 / 2021-004594-32: IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)

Active, not recruiting
3
407
Europe, US, RoW
IO102-IO103, Pembrolizumab
IO Biotech, Syneos Health, Merck Sharp & Dohme LLC
Metastatic Melanoma, Unresectable Melanoma
07/25
09/27
ABSIDE, NCT01973322 / 2012-001410-41: Vaccination With Autologous Dendritic Cells Loaded With Autologous Tumor Lysate or Homogenate Combined With Immunomodulating Radiotherapy and/or Preleukapheresis IFN-alfa in Patients With Metastatic Melanoma: a Randomized "Proof-of-principle" Phase II Study

Completed
2
34
Europe
arm 1: DC Vaccine + RT, vaccine + radiotherapy, arm 2: DC Vaccine + IFN-alfa, vaccine + drug, arm 3: both arm 1 and 2 + RT, vaccine + radiotherapy + drug, arm 4: DC Vaccine, vaccine
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
Malignant Melanoma of Skin Stage III, Malignant Melanoma of Skin Stage IV
09/23
06/24
NCT05299580 / 2019-004760-21: "Dabrafenib and Trametinib in Circulating Free DNA BRAFV600 Mutated Metastatic Melanoma Patients: a Prospective Phase II, Open Label, Multicentre Study - (Bioliquid TAILOR Study - BIOTAILOR)"

Withdrawn
2
35
Europe
dabrafenib, Trametinib
Fondazione Melanoma Onlus, Novartis Farma S.p.A.
Melanoma
03/23
03/23
NCT05529316: A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma

Active, not recruiting
2
174
Europe, US, RoW
Botensilimab, AGEN1181, Balstilimab, AGEN2034
Agenus Inc.
Advanced Melanoma
02/28
02/28
NEO-TIM, NCT04722575 / 2018-004841-17: Combination or Sequence of Vemurafenib, Cobimetinib, and Atezolizumab in High-risk, Resectable Melanoma

Active, not recruiting
2
95
Europe
Cobimetinib 20 MG Oral Tablet, Cotellic, Vemurafenib 240 Mg Oral Capsule, Zelboraf, Atezolizumab 1200 MG in 20 ML Injection, Tecentriq
Fondazione Melanoma Onlus, Clinical Research Technology S.r.l.
Melanoma
12/23
06/27
MESOVAX, NCT03546426: Pembrolizumab Plus Autologous Dendritic Cell Vaccine in Patients with PD-L1 Negative Advanced Mesothelioma Who Have Failed Prior Therapies

Active, not recruiting
1
18
Europe
Pembrolizumab, Autologous dendritic cells, Interleukin-2
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
Mesothelioma, Malignant, PD-L1 Negative, Advanced Cancer, Progressive Disease
01/27
09/28
NCT04759846: Hepatic Impairment Study of Encorafenib in Combination With Binimetinib in BRAF Melanoma

Withdrawn
1
12
Europe, RoW
Encorafenib + Binimetinib, Braftovi + Mektovi
Pierre Fabre Medicament
BRAF V600 Mutation, Unresectable Melanoma, Metastatic Melanoma, Hepatic Impairment
05/23
05/23
Giorgi, Ugo De
NCT04460807 / 2018-000693-30: Exemestane in Hormone Receptor Positive High Grade Ovarian Cancer

Terminated
3
23
Europe
Exemestane, Mestane, Placebo oral tablet
Ente Ospedaliero Ospedali Galliera, Istituto Di Ricerche Farmacologiche Mario Negri, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Federation of Italian Cooperative Oncology Groups
Ovarian Cancer
04/23
04/23
innovaTV 301, NCT04697628 / 2019-001655-39: Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer

Active, not recruiting
3
502
Europe, Canada, Japan, US, RoW
tisotumab vedotin, TIVDAK, PF-08046057, topotecan, vinorelbine, gemcitabine, irinotecan, pemetrexed
Seagen, a wholly owned subsidiary of Pfizer, Genmab
Cervical Cancer
07/23
05/26
postMONARCH, NCT05169567 / 2021-002301-10: Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer

Active, not recruiting
3
368
Europe, US, RoW
Abemaciclib, Fulvestrant, Placebo
Eli Lilly and Company, Eli Lilly and Company
Breast Neoplasm, Neoplasm Metastasis
02/24
02/26
PEACE III, NCT02194842 / 2014-001787-36: Phase III Radium 223 mCRPC-

Active, not recruiting
3
446
Europe, Canada, RoW
Ra223, Enzalutamide
European Organisation for Research and Treatment of Cancer - EORTC, Bayer, Astellas Pharma Europe Ltd., UNICANCER, Canadian Urologic Oncology Group, Latin American Cooperative Oncology Group, Cancer Trials Ireland
Prostate Cancer
02/24
12/28
PEGASUS, NCT02799706: Trial Comparing Irradiation Plus Long Term Adjuvant Androgen Deprivation With GnRH Antagonist Versus GnRH Agonist Plus Flare Protection in Patients With Very High Risk Localized or Locally Advanced Prostate Cancer

Active, not recruiting
3
885
Europe
Degarelix, approved GnRH agonist, Radiotherapy
European Organisation for Research and Treatment of Cancer - EORTC
Prostate Cancer
08/23
06/26
NCT02584478 / 2021-003871-32: Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002)

Active, not recruiting
3
294
Europe, US, RoW
AL3818, Anlotinib Hydrochloride, Anlotinib, Catequentinib, Paclitaxel, Pegylated Liposomal Doxorubicin (PLD), Topotecan, Daily Topotecan, Weekly Topotecan, Carboplatin, Paraplatin, Taxol
Advenchen Laboratories, LLC, Advenchen Laboratories, LLC
Endometrial Carcinoma, Ovarian Carcinoma, Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma, Cervical Carcinoma
10/24
12/24
ZEST, NCT04915755 / 2020-003973-23: Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease

Calendar Jan 2025 - Dec 2025: Pivotal data from ZEST trial for HER2-negative BRCA-mutated or triple-negative breast cancer
Active, not recruiting
3
43
Europe, Canada, Japan, US, RoW
Niraparib, Placebo
GlaxoSmithKline
Neoplasms, Breast
06/24
12/25
ELAINE 3, NCT05696626: Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

Recruiting
3
500
Europe, Canada, US, RoW
Lasofoxifene in combination with abemaciclib, Fulvestrant in combination with abemaciclib
Sermonix Pharmaceuticals Inc.
Metastatic Breast Cancer
04/27
04/28
CYCLONE 3, NCT05288166: A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)

Active, not recruiting
3
900
Europe, Canada, Japan, US, RoW
Abemaciclib, LY2835219, Abiraterone, Prednisone or Prednisolone, Placebo for Abemaciclib
Eli Lilly and Company
Prostatic Neoplasms, Neoplasm Metastasis, Urogenital Neoplasms, Physiological Effects of Drugs, Antineoplastic Agents, Antineoplastic Agents, Hormonal, Androgens, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Abiraterone Acetate, Steroid Synthesis Inhibitors, Cytochrome P-450, Enzyme Inhibitors, Prednisone, Prednisolone, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6
02/24
10/27
PEACE6-Unfit, NCT04916613 / 2020-003663-26: ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable)

Recruiting
3
300
Europe
Darolutamide 300 mg, Nubeqa®, Placebo, Androgen deprivation therapy, ADT
UNICANCER, Bayer
Prostate Cancer Metastatic
03/28
09/37
TREAT ctDNA, NCT05512364: Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse

Recruiting
3
220
Europe
Elacestrant, Tamoxifen, Letrozole 2.5mg, Anastrozole 1mg, Exemestane 25 MG
European Organisation for Research and Treatment of Cancer - EORTC, Breast International Group, Menarini Group
ER-positive Breast Cancer, HER2-negative Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer
07/28
05/30
LEPRE, NCT05601700 / 2020-003066-39: Letrozole for Estrogen/Progesterone Receptor Positive Low-grade Serous Epithelial Ovarian Cancer ( Trial)

Recruiting
3
132
Europe
Letrozole tablets, carboplatin AUC 5 and paclitaxel 175 mg/m2
Ente Ospedaliero Ospedali Galliera, Istituto Di Ricerche Farmacologiche Mario Negri, Humanitas Hospital, Italy
Carcinoma, Ovarian Epithelial, Low Grade Serous Adenocarcinoma of Ovary
09/29
09/29
ENGOT en-21, NCT05797831: Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer

Recruiting
2/3
268
Europe, Canada, US, RoW
Navtemadlin, KRT-232, Navtemadlin Placebo
Kartos Therapeutics, Inc., European Network of Gynaecological Oncological Trial Groups (ENGOT), GOG Foundation
Endometrial Cancer
08/25
07/27
NCT02533765 / 2014-005095-28: Olaparib as Salvage Treatment for Cisplatin-resistant Germ Cell Tumor

Completed
2
18
Europe
Olaparib, AZD2281
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
Neoplasms, Germ Cell and Embryonal
09/18
02/23
LU-PSMA, NCT03454750 / 2016-002732-32: Radiometabolic Therapy (RMT) With 177Lu PSMA 617 in Advanced Castration Resistant Prostate Cancer (CRPC)

Completed
2
143
Europe
177Lu-PSMA
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
Metastatic Castration Resistant Prostate Cancer, 68Ga-PSMA PET/CT Positive
05/24
05/24
HERMIONE-7, NCT04227327: Study Evaluating Abemaciclib + Aromatase Inhibitors in HR+, HER2- Advanced Breast Cancer Patients

Active, not recruiting
2
31
Europe
Abemaciclib, Aromatase Inhibitors
University of Milano Bicocca
Advanced Breast Cancer
12/23
12/23
NCT05085002 / 2021-005238-40: A Study of Lerociclib in Participants With Advanced Breast Cancer

Terminated
2
100
Europe, US, RoW
Lerociclib + Letrozole or Fulvestrant
EQRx, Inc.
Advanced Breast Cancer
11/23
11/23
SGNLVA-005, NCT04032704 / 2019-001946-17: A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors

Terminated
2
205
Europe, US, RoW
ladiratuzumab vedotin, SGN-LIV1A, pembrolizumab, Keytruda
Seagen Inc., Merck Sharp & Dohme LLC
Small Cell Lung Cancer, Non-small Cell Lung Cancer, Squamous, Non-small Cell Lung Cancer, Non-squamous, Head and Neck Squamous Cell Carcinoma, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Prostate Cancer, Melanoma
11/23
11/23
ROME, NCT04591431 / 2018-002190-21: The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy

Active, not recruiting
2
400
Europe
Erlotinib, Trastuzumab, Trastuzumab emtansine, Pertuzumab, Lapatinib, Everolimus, Vemurafenib, Cobimetinib, Alectinib, Brigatinib, Palbociclib, Ponatinib, Vismogedib, Itacitinib, Ipatasertib, Entrectinib, Atezolizumab, Nivolumab, Ipilimumab, Pemigatinib, Oncology Drugs, Pralsetinib, Selpercatinib, Talazoparib, Tepotinib, Alpelisib
Fondazione per la Medicina Personalizzata
Breast Cancer, Gastrointestinal Cancer, Non Small Cell Lung Cancer, Other Cancer
12/24
06/25
JAVELIN Bladder Medley, NCT05327530: A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma

Active, not recruiting
2
256
Europe, Canada, US, RoW
Avelumab, MSB0010718C, Sacituzumab Govitecan, IMMU-132, Trodelvy™, GS-0132, M6223, NKTR-255
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany; Gilead Sciences; Nektar Therapeutics
Locally Advanced or Metastatic Urothelial Carcinoma
01/25
01/25
RAPSON, NCT03230734 / 2016-004452-29: Sequencing of Radium-223 and Docetaxel in Symptomatic Bone-only Metastatic Castration-resistant Prostate Cancer

Active, not recruiting
2
70
Europe
Radium-223, Docetaxel
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori, Bayer
Metastatic Castration-resistant Prostate Cancer
07/25
07/25
PREcoopERA, NCT05896566: A Window-of-Opportunity Trial of Giredestrant +/- Triptorelin vs. Anastrozole + Triptorelin in Premenopausal Patients With ER-positive/HER2-negative Early Breast Cancer

Recruiting
2
220
Europe
Giredestrant, Triptorelin, Anastrozole
ETOP IBCSG Partners Foundation, Hoffmann-La Roche
Breast Cancer
06/26
06/26
BIO-META, NCT02284581: Evaluation of Medical Treatments in MBC Patients According Biological Subtype and Line of Treatments

Recruiting
N/A
10000
Europe
Consorzio Oncotech
Metastatic Breast Cancer
06/23
12/25
IRSTB030, NCT03381326: CTC, Free DNA, Stem Cells and EMT-related Antigens as Biomarkers of Activity of Cabazitaxel in CRPC.

Active, not recruiting
N/A
104
Europe
blood and FFPE sample collection
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
Prostate Cancer, Metastatic Cancer, Castration-resistant Prostate Cancer, Circulating Tumor Cells
10/19
12/23
HERMIONE-13, NCT05173103: Retrospective Study of 2nd-line Therapies After CDK4/6i + Hormonal Therapy in HR+/HER2- Advanced Breast Cancer

Recruiting
N/A
150
Europe
University of Milano Bicocca
Advanced Breast Cancer, Hormone Receptor Positive Breast Carcinoma, HER2-negative Breast Cancer
01/24
01/24
NCT06235268: Prospective and Multicenter Italian Registry of Locally Advanced-Metastatic Urothelial Carcinoma

Recruiting
N/A
1000
Europe
Active systemic or non-systemic treatment (palliative or observation procedure)
Federation of Italian Cooperative Oncology Groups
Carcinoma, Urothelial
11/25
11/25
NCT04416672: Validation of the Italian Version of the PRO-CTCAE

Recruiting
N/A
3675
Europe
PRO-CTCAE items
National Cancer Institute, Naples
Malignant Neoplasms
07/24
07/24
Ridolfi, Laura
NCT01884961 / 2012-001786-32: Radiotherapy As an Immunological Booster in Patients with Metastatic Melanoma or Renal Cell Carcinoma Treated with High-dose Interleukin-2

Completed
2
46
Europe
Boost of radiotherapy + high dose IL-2 treatment
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
Metastatic Renal Cell Cancer, Malignant Melanoma, Metastatic
06/21
01/25
RaC-Ad, NCT04166006 / 2019-000793-27: A Phase II Study on Adjuvant Vaccination with Dendritic Cells Loaded with Autologous Tumor Homogenate in Resected Stage IV Rare Cancers.

Recruiting
2
51
Europe
Autologous DC vaccine, Interleukin-2
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori, IRST IRCCS
Head Neck Tumors, Neuroendocrine Tumors, Soft Tissue Sarcoma, Rare Cancer, Vaccination
04/27
12/31
Combi G-Vax, NCT04523688 / 2020-003755-15: Vaccination with Autologous Dendritic Cells Loaded with Autologous Tumour Homogenate in Glioblastoma

Recruiting
2
28
Europe
Autologous Dendritic Cells (DC) vaccine, Temozolomide
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori, IRST IRCCS
Glioblastoma, Vaccination
07/25
12/25
OMNIA-1, NCT05578872 / 2021-006711-29: A Study of ANV419 Alone or in Combination with Approved Treatment in Patients with Cutaneous Melanoma ().

Completed
1/2
29
Europe, US
ANV419, Pembrolizumab, Ipilimumab
Anaveon AG, Anaveon AG
Melanoma (Skin), Cutaneous Melanoma, Adult Disease, Advanced Solid Tumor, Metastatic Melanoma
08/24
08/24
Lolli, Cristian
No trials found

Download Options